- Home
- IOVA
as 12-17-2024 4:00pm EST
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 2.6B | IPO Year: | N/A |
| Target Price: | $23.33 | AVG Volume (30 days): | 5.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.70 - $18.33 | Next Earning Date: | 11-07-2024 |
| Revenue: | $90,858,000 | Revenue Growth: | 12751.20% |
| Revenue Growth (this year): | 13758.7% | Revenue Growth (next year): | 171.64% |
Stock Insider Trading Activity of Iovance Biotherapeutics Inc. (IOVA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Maynard Ryan D | IOVA | Director | Nov 12 '24 | Sell | $10.06 | 50,000 | $503,000.00 | 7,500 |
Latest Iovance Biotherapeutics Inc. News
IOVA Breaking Stock News: Dive into IOVA Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Motley Fool
6 days ago
Prediction: This Stock Will Beat the Market in 2025
Motley Fool
11 days ago
3 Monster Stocks to Hold for the Next 10 Years
Simply Wall St.
15 days ago
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63%
Motley Fool
21 days ago
Is Iovance Biotherapeutics Stock a Millionaire Maker?
MT Newswires
22 days ago
Iovance Biotherapeutics Names Raj Puri as Chief Regulatory Officer
GlobeNewswire
22 days ago
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
Motley Fool
25 days ago
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back
Compare IOVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IOVA Iovance Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.